Ex Vivo Treatment with a Novel Synthetic Aminoglycoside NB54 in Primary Fibroblasts from Rett Syndrome Patients Suppresses MECP2 Nonsense Mutations

MeCP2 deficiency down-regulates specific nuclear proteins that could be partially recovered by valproic acid in vitro

(2010) Manuela Vecsler et al.   Epigenetics

Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model

(2010) Cornelia Brendel et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Exogenous Brain-Derived Neurotrophic Factor Rescues Synaptic Dysfunction in Mecp2-Null Mice

(2010) D. D. Kline et al.   JOURNAL OF NEUROSCIENCE

Neuronal MeCP2 Is Expressed at Near Histone-Octamer Levels and Globally Alters the Chromatin State

(2010) Peter J. Skene et al.   MOLECULAR CELL

Development of Novel Aminoglycoside (NB54) with Reduced Toxicity and Enhanced Suppression of Disease-Causing Premature Stop Mutations

(2009) Igor Nudelman et al.   JOURNAL OF MEDICINAL CHEMISTRY

Suppression of Nonsense Mutations in Rett Syndrome by Aminoglycoside Antibiotics

(2009) Cornelia Brendel et al.   PEDIATRIC RESEARCH

MeCP2, a Key Contributor to Neurological Disease, Activates and Represses Transcription

(2008) M. Chahrour et al.   SCIENCE

Designer aminoglycosides: the race to develop improved antibiotics and compounds for the treatment of human genetic diseases

(2007) Mariana Hainrichson et al.   ORGANIC & BIOMOLECULAR CHEMISTRY